Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CBLB | Q13191 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224525 | 0.93 | MAPT (0.35) | MAPTMAPK1POLBCBLBPRKCA | |
| SCHEMBL14224526 | 0.91 | CBLB (0.36) | CBLBHTTPRKCA | |
| SCHEMBL14224527 | 0.89 | CBLB (0.36) | CBLBHTTPRKCA | |
| SCHEMBL14224803 | 0.86 | FPR1 (0.42) | MAPTSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL14224802 | 0.84 | MAPT (0.41) | MAPTSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL14224552 | 0.84 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL14224539 | 0.83 | NPC1 (0.43) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL14224761 | 0.83 | MAPT (0.50) | MAPTSMN1; SMN2NPC1RAB9AMAPK1 | |
| SCHEMBL14224529 | 0.81 | FOXO1 (0.41) | MAPTSMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL14426984 | 0.79 | MAPT (0.41) | MAPTSMN1; SMN2NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7265129-B2 | Anti-infective biaryl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090816-A1 | ANTI-INFECTIVE BIARYL COMPOUNDS | QTRT1, Q6ZSR9, QTRT2 | MAPT 4305/4885SMN1; SMN2 4635/4885NPC1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.